Loading...
XSTO
GENO
Market cap142mUSD
Dec 05, Last price  
20.35SEK
1D
-0.49%
1Q
-11.52%
Jan 2017
698.04%
IPO
-58.42%
Name

Genovis AB

Chart & Performance

D1W1MN
XSTO:GENO chart
P/E
40.57
P/S
10.24
EPS
0.50
Div Yield, %
Shrs. gr., 5y
0.74%
Rev. gr., 5y
16.58%
Revenues
130m
-17.62%
379,653986,1781,596,0192,856,0836,080,8738,912,0938,252,06413,268,50118,541,94122,867,26634,567,98060,549,14161,029,72193,017,543102,386,899158,232,000130,358,000
Net income
33m
-46.48%
-27,149,579-17,558,226-11,291,508-13,607,963-19,915,127-15,852,513-22,048,663-19,905,623-15,031,013-7,948,532-1,710,3819,551,5766,445,90224,777,38511,191,00061,500,00032,916,000
CFO
37m
-45.22%
-16,760,756-13,695,153-10,484,825-12,149,160-14,847,903-12,467,813-22,192,335-16,117,301-16,075,111-8,355,087-1,249,59513,125,5533,755,19345,918,901-927,94767,752,00037,116,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Genovis AB (publ.) designs, develops, and sells tools for development of drugs for customers in the pharmaceutical and medical device industries. The company offers FabALACTICA, a cysteine protease that digests human IgG1; FabRICATOR, an enzyme that primarily digests the hinge region of IgG; and FabRICATOR Z, an enzyme for the digestion of mouse IgG2a and IgG3, as well as for generating a homogenous pool of F(ab')2 and Fc fragments. It also provides FabULOUS (SpeB), an enzyme for the digestion of IgG in the hinge region; and GingisKHAN, a cysteine protease that digests human IgG1 at a specific site above the hinge. In addition, the company offers GingisREX, a cysteine protease that specifically digests peptide bonds C-terminally to arginine residues; and IgGZERO (EndoS), an endoglycosidase from Streptococcus pyogenes that specifically hydrolyzes N-linked glycans in the Fc-region of native IgG. Further, it provides IgGZERO LE, an endoglycosidase acting on complex type N-glycans from Streptococcus pyogenes; deGlycIT, an IgGZERO (EndoS) enzyme for agarose beads for deglycosylation of Fc-glycans; GlycINATOR an endoglycosidase from Streptococcus pyogenes that hydrolyzes the all glycoforms structure; and GlycINATOR (EndoS2), an endoglycosidase from Streptococcus pyogenes that specifically hydrolyzes glycans at the Fc glycosylation site of IgG. Additionally, the company offers GlyCLICK, a site-specific conjugation technology used for IgG on enzymatic remodeling of the Fc glycans and click chemistry; SialEXO, a sialidase product for the removal and analysis of sialic acids; enzymes for O-glycans; and antibody fragmentation services, as well as operates online store for its products. It serves pharmaceutical and biotech, contract research, and contract manufacturing companies in Sweden, Europe, North America, and Asia. The company has a collaboration with Waters Corporation. Genovis AB (publ.) was founded in 1999 and is based in Lund, Sweden.
IPO date
Nov 11, 2005
Employees
38
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT